Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 8/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6614542 | 0.99 | CNR1 (0.47) | CNR1CHEK1CNR2NPC1RAB9A | |
| SCHEMBL6817225 | 0.82 | HSD11B1 (0.42) | CNR1MDM2HPGD | |
| SCHEMBL6817228 | 0.77 | CNR1 (0.50) | CNR1CNR2NPC1RAB9AL3MBTL1 | |
| SCHEMBL6601518 | 0.75 | CNR1 (0.53) | CNR1CNR2 | |
| SCHEMBL3455501 | 0.70 | RAB9A (0.72) | NPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL8210765 | 0.70 | RAB9A (0.72) | NPC1RAB9AHPGDSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6614304 | 0.69 | CNR1 (0.55) | CNR1CNR2 | |
| SCHEMBL16043466 | 0.69 | RAB9A (0.69) | NPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL22720173 | 0.69 | RAB9A (0.57) | CHEK1NPC1RAB9AL3MBTL1SMN1; SMN2 | |
| SCHEMBL6698259 | 0.67 | CNR1 (0.77) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040267028-A1 | Preparation and use of pyrrole derivatives for treating obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-12-30 | — | — | US | disclosed |
| EP-1432679-A1 | PREPARATION AND USE OF PYRROLE DERIVATIVES FOR TREATING OBESITY | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003027069-A1 | PREPARATION AND USE OF PYRROLE DERIVATIVES FOR TREATING OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040267028-A1 | Preparation and use of pyrrole derivatives for treating obesity | PGC, GIPR, GPR119 | CNR1 118/4885CHEK1 4665/4885CNR2 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.